ES2988151T3 - Composición que comprende resveratrol, glicina, arginina y cisteína para su uso en el tratamiento del síndrome metabólico - Google Patents

Composición que comprende resveratrol, glicina, arginina y cisteína para su uso en el tratamiento del síndrome metabólico Download PDF

Info

Publication number
ES2988151T3
ES2988151T3 ES17810608T ES17810608T ES2988151T3 ES 2988151 T3 ES2988151 T3 ES 2988151T3 ES 17810608 T ES17810608 T ES 17810608T ES 17810608 T ES17810608 T ES 17810608T ES 2988151 T3 ES2988151 T3 ES 2988151T3
Authority
ES
Spain
Prior art keywords
composition
formulation
cells
resveratrol
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17810608T
Other languages
English (en)
Spanish (es)
Inventor
De La Vega Horacio Astudillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Application granted granted Critical
Publication of ES2988151T3 publication Critical patent/ES2988151T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES17810608T 2015-06-08 2017-06-08 Composición que comprende resveratrol, glicina, arginina y cisteína para su uso en el tratamiento del síndrome metabólico Active ES2988151T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (1)

Publication Number Publication Date
ES2988151T3 true ES2988151T3 (es) 2024-11-19

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17810608T Active ES2988151T3 (es) 2015-06-08 2017-06-08 Composición que comprende resveratrol, glicina, arginina y cisteína para su uso en el tratamiento del síndrome metabólico

Country Status (8)

Country Link
US (1) US10285963B2 (enExample)
JP (1) JP2019521184A (enExample)
CN (1) CN109890369B (enExample)
BR (1) BR112018075395A2 (enExample)
CA (1) CA3027048A1 (enExample)
ES (1) ES2988151T3 (enExample)
MX (1) MX365886B (enExample)
RU (1) RU2749950C2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JPWO2008143182A1 (ja) * 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Also Published As

Publication number Publication date
RU2018147077A3 (enExample) 2020-09-21
CN109890369B (zh) 2022-04-29
JP2019521184A (ja) 2019-07-25
BR112018075395A2 (pt) 2019-04-02
US10285963B2 (en) 2019-05-14
CA3027048A1 (en) 2017-12-14
MX365886B (es) 2019-06-19
CN109890369A (zh) 2019-06-14
US20160354331A1 (en) 2016-12-08
RU2018147077A (ru) 2020-07-10
RU2749950C2 (ru) 2021-06-21
MX2017007448A (es) 2018-09-10

Similar Documents

Publication Publication Date Title
Sheng et al. Grape seed proanthocyanidin extract ameliorates dextran sulfate sodium-induced colitis through intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokines and gut microbiota modulation
Tsuda Recent progress in anti-obesity and anti-diabetes effect of berries
Vendrame et al. Potential factors influencing the effects of anthocyanins on blood pressure regulation in humans: a review
Vinayagamoorthi et al. Antioxidants preserve redox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine phosphorylation and insulin resistance
Talagavadi et al. Cyanidin-3-O-β-glucoside and protocatechuic acid activate AMPK/mTOR/S6K pathway and improve glucose homeostasis in mice
Thirupathi et al. Modulatory effects of taurine on metabolic and oxidative stress parameters in a mice model of muscle overuse
Aparecida Paiva et al. Carqueja (Baccharis trimera) protects against oxidative stress and β‐amyloid‐induced toxicity in Caenorhabditis elegans
Fuentes et al. Quercetin oxidation metabolite present in onion peel protects caco-2 cells against the oxidative stress, NF-kB activation, and loss of epithelial barrier function induced by NSAIDs
Alsolmei et al. Polyphenol-enriched plum extract enhances myotubule formation and anabolism while attenuating colon cancer-induced cellular damage in C2C12 cells
Ielciu et al. Flavonoid composition, cellular antioxidant activity and (myelo) peroxidase inhibition of a Bryonia alba L.(Cucurbitaceae) leaves extract
US10039798B2 (en) Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm
González-Jamett et al. Oxidative stress, inflammation and connexin hemichannels in muscular dystrophies
Lee Regulation of cytochrome c oxidase by natural compounds resveratrol,(–)-epicatechin, and betaine
Isaak et al. Supplementing diet with Manitoba lingonberry juice reduces kidney ischemia‐reperfusion injury
Chen et al. Eucommia ulmoides male flower as a remarkable edible floral resource exerts lifespan/healthspan-promoting effects on Caenorhabditis elegans
ES2988151T3 (es) Composición que comprende resveratrol, glicina, arginina y cisteína para su uso en el tratamiento del síndrome metabólico
Takin et al. Effect of total Khaya senegalensis (Meliaceae) barks extracts on hepatic liberation of glucose
Repici et al. Ulva pertusa modulated colonic oxidative stress markers and clinical parameters: a potential adjuvant therapy to manage side effects during 5-FU regimen
EP3470060B1 (en) Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
OA19128A (en) Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes.
HK40010029B (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
HK40010029A (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
Mohammed et al. Anti-diabetic efficacy of young and mature leaf extract of Mangifera indica
Gothai et al. In vitro and in vivo-scientific evaluation on cytotoxicity and genotoxicity of traditional medicinal plant Couroupita guianensis aubl
Ding et al. Dietary propionate induces intestinal oxidative stress via inhibition of SIRT3-mediated SOD2 depropionylation